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Identity 
Other names: ATOD4, CIS3, Cish3, MGC71791, 
SOCS-3, SSI-3, SSI3 




Size: 3300 bases. 
Transcription 
2 introns.  
Transcription generates 3 different mRNAs, 2 spliced 
variants and 1 unspliced form. 
Protein 
Description 
225 amino acids, 24770 Da. 
Expression 
Widely expressed in normal and tumor tissues. 







SOCS is a negative regulator of cytokines that signal 
through the JAK/STAT pathway. It binds to tyrosine 
kinase receptors such as gp130 subunit of receptors.  
It interacts with cytokine receptors or JAK kinases and 
interaction with growth factor receptors (insulin-like 
growth factor-I, insulin, fibroblast growth factor). It 
inhibits JAK2 kinase activity.  
Part of the ubiquitin-protein ligase complex which 
contains elongin, RNF7, and CUL5.  
Binding to leptin.  
Tumor promoting or tumor suppressive functions. 
Antagonizing cAMP-antiproliferative effects. SOCS3 
suppresses erythropoietin in fetal liver and IL-6 
signaling in vivo. 
Mutations 
Note 
Mutations not detected. 
 
 















SOCS-3 acts as a tumor suppressor and is frequently 
lost in the disease. Its transient transfection in lung 
cancer cell lines leads to a decrease in proliferation. 
Liver cancer 
Note 
SOCS-3 is silenced by methylation. SOCS-3 is a tumor 
suppressor in this malignancy. It is implicated in 
regulation of migration of cancer cells. SOCS-3 
deletion enhances JAK/STAT and FAK signaling. 
Barret's adenocarcinoma 
Note 




SOCS-3 expression is lost through promoter 
methylation. 
Head and neck squamous cell cancer 
Note 
SOCS-3 is frequently down-regulated as a result of 
promoter methylation. It causes a growth inhibition. 
Hematological malignancies 
Note 
SOCS-3 inhibits megakaryocytic growth, 
overexpression of SOCS-3 is associated with a 




SOCS-3 is a tumor promoter in melanoma and is 
constitutively expressed in several cell lines. 
Prostate cancer 
Note 
SOCS-3 stimulates proliferation and inhibits apoptosis 
in prostate cancer cells which do not express the 
androgen receptor.  
It may also antagonize the effects of fibroblasts growth 
factor and mitogen-activated protein kinases.  
In androgen-sensitive prostate cancer cells, SOCS-3 is 
induced by androgen and may inhibit androgen-
stimulated proliferation and secretion. 
Diabetes 
Note 




Loss of protein expression and promoter 
hypermethylation occur in lung, liver cancer, head and 
neck squamous cell cancer. Overexpression occurs in 
melanoma and prostate cancer. 
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